In contrast to the results on MSI, Lal and colleagues showed that RAS mutation predicts for a relatively poor immune infiltration and low inhibitory molecule expression. KRAS and NRAS mutant CRC had significantly lowered levels of CD4+ T cells [99]. The gene discussed is KRAS; the disease is colorectal carcinoma.